- Home
- ATYR vs DRDB Comparison
ATYR vs DRDB Comparison
Compare ATYR & DRDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATYR | DRDB |
|---|---|---|
| Founded | 2005 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 319.5M |
| IPO Year | 2015 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ATYR | DRDB |
|---|---|---|
| Price | $0.81 | $10.42 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 57.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | N/A |
| P/E Ratio | ★ N/A | $595.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $9.87 |
| 52 Week High | $7.29 | $10.47 |
Technical Indicators
Market Signals| Indicator | ATYR | DRDB |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 47.42 |
| Support Level | $0.70 | $10.43 |
| Resistance Level | $0.86 | $10.47 |
| Average True Range (ATR) | 0.06 | 0.01 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 79.46 | 9.09 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.